Investigational drug · Phase 3
Abexinostat
Also called: PCI-24781
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
15
Any phase or sponsor naming "Abexinostat"
First trial start
2018
Jul 17, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Abexinostat", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Lymphoma, Follicular
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma
- Renal Cell Carcinoma
- Non Hodgkin Lymphoma
Approved drugs for the same conditions: Kidney cancer (renal cell carcinoma) · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Oncology · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Abexinostat" as an intervention, largest first.
- A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)Pivotal-lookingRecruiting
Xynomic Pharmaceuticals, Inc.Industry
NCT03592472 · 413 participants (planned) · Start Jul 17, 2018 · Primary completion Dec 30, 2026
Drug: Pazopanib; Abexinostat · For: Renal Cell Carcinoma
Sites: Phoenix, Arizona; Sacramento, California; San Francisco, California · 38 sites in all
Xynomic Pharmaceuticals, Inc.Industry
NCT03936153 · 170 participants (planned) · Start Jan 20, 2020 · Primary completion Jul 31, 2026
Drug: abexinostat · For: Diffuse Large B-cell Lymphoma (DLBCL)
Sites: Beijing, China; Chengdu, China; Dalian, China · 23 sites in all
- Study of Abexinostat in Patients With Relapsed or Refractory Follicular LymphomaActive, not recruiting
Xynomic Pharmaceuticals, Inc.Industry
NCT03600441 · 139 participants (planned) · Start Aug 27, 2018 · Primary completion Dec 31, 2027
Drug: Abexinostat · For: Follicular Lymphoma
Sites: Park Ridge, Illinois; Louisville, Kentucky; Lake Success, New York · 15 sites in all
Pamela MunsterAcademic, hospital or other
NCT01543763 · 90 participants · Start Jun 25, 2012 · Primary completion Jan 31, 2024
Drug: PZP115891, PCI-24781 · For: Metastatic Solid Tumors
Sites: San Francisco, California
- A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaActive, not recruiting
Xynomic Pharmaceuticals, Inc.Industry
NCT03934567 · 87 participants · Start Apr 22, 2020 · Primary completion Jan 29, 2025
Drug: Abexinostat · For: Lymphoma, Follicular
Sites: Beijing, China; Changchun, China; Chengdu, China · 26 sites in all
Pharmacyclics LLC.AbbVie (ABBV)
NCT00724984 · 55 participants · Start Jul 2008 · Primary completion Nov 2012
Drug: PCI-24781 · For: Lymphoma; Hodgkin Disease; Lymphoma, Non-Hodgkin
Sites: San Francisco, California; Chicago, Illinois; Lafayette, Indiana · 8 sites in all
Pharmacyclics LLC.AbbVie (ABBV)
NCT00473577 · 40 participants (planned) · Start Aug 2005 · Primary completion Nov 2007
Drug: CRA-24781 · For: Hematologic Neoplasms; Neoplasms
Sites: Chicago, Illinois
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompleted
Pharmacyclics LLC.AbbVie (ABBV)
NCT00562224 · 36 participants (planned) · Start Nov 2007 · Primary completion Jun 2010
Drug: PCI-24781 · For: Neoplasms by Site; Lymphoma, Non-hodgkin; Hodgkin Disease and 2 more
Sites: Greenbrae, California; Chicago, Illinois; Nashville, Tennessee · 4 sites in all
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompleted
Rahul AggarwalAcademic, hospital or other
NCT03590054 · 35 participants · Start Aug 20, 2018 · Primary completion Nov 30, 2023
Drug: Abexinostat; Pembrolizumab · For: Stage III Cutaneous Melanoma; Stage IV Cutaneous Melanoma; Locally Advanced Melanoma and 18 more
Sites: San Francisco, California
University of NebraskaAcademic, hospital or other
NCT05698524 · 24 participants (planned) · Start Jun 26, 2023 · Primary completion Jul 2027
Drug: PCI 24781; Temozolomide · For: Recurrent High Grade Glioma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma and 2 more
Sites: Omaha, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- A rapid sporozoite viability assay identifies leads and targetable enzymatic activities against the zoonotic Cryptosporidium parvum.
Jiang P, Wang D, Wang Y, et al. · Int J Parasitol Drugs Drug Resist 2026
- Abexinostat attenuates temozolomide-resistant glioma stem cells.
Perumalsamy B, Vengoji R, Thiraviyam A, et al. · Neuro Oncol 2026
- Mapping Non-Homologous Pocket Compatibilities to Identify Hidden Drug-Target Relationships: A Pocket Hopping Framework.
Zhang Y, Yang T, Niu B, et al. · J Med Chem 2026
- Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
Gui L, Liu H, Wang H, et al. · Signal Transduct Target Ther 2026
- The role of SLC22A4 in Acute Myeloid Leukaemia.
Li Y, Li Y, Cheng W · Mediterr J Hematol Infect Dis 2025
- Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.
Gui L, Xie Z, Qin Y, et al. · BMC Cancer 2025
Also in development for Lymphoma, Follicular
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.